Cytokinetics Inc. (CYTK) is a publicly traded Healthcare sector company. As of May 21, 2026, CYTK trades at $79.64 with a market cap of $10.21B and a P/E ratio of -11.44. CYTK moved +2.97% today. Year to date, CYTK is +28.58%; over the trailing twelve months it is +141.18%. Its 52-week range spans $29.31 to $80.20. Analyst consensus is strong buy with an average price target of $100.18. Rallies surfaces CYTK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cytokinetics Opens Free Registration for May 29 CLIMB Symposium with Phase 3 Updates: Cytokinetics will host its third annual CLIMB symposium on May 29 at San Francisco’s Mission Bay Conference Center; free registration is open until May 22 with limited capacity. The forum covers cardiac and skeletal muscle biology, including positive Phase 3 ACACIA-HCM topline results and planned FDA data discussions.
| Metric | Value |
|---|---|
| Price | $79.64 |
| Market Cap | $10.21B |
| P/E Ratio | -11.44 |
| EPS | $-6.84 |
| Dividend Yield | 0.00% |
| 52-Week High | $80.20 |
| 52-Week Low | $29.31 |
| Volume | 129 |
| Avg Volume | 0 |
| Revenue (TTM) | $105.81M |
| Net Income | $-829.61M |
| Gross Margin | 0.00% |
19 analysts cover CYTK: 0 strong buy, 16 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $100.18.